-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Malaria [strain 7G8] Vaccine in Malaria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Malaria [strain 7G8] Vaccine in Malaria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Malaria [strain 7G8] Vaccine in Malaria Drug Details: Vaccine candidate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-794 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-794 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMG-794 in Triple-Negative Breast Cancer (TNBC) Drug Details: AMG-794 is...
-
Product Insights
Malaria Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Malaria Clinical Trial Report Overview A total of 1,673 malaria clinical trials were conducted as of January 2024. The malaria clinical trial report provides a comprehensive understanding of the malaria clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · Europe · North America · ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Peripheral T-Cell Lymphomas (PTCL) Drug Details: BP-1002...
-
Product Insights
Malaria – Drugs In Development, 2023
Global Markets Direct’s, ‘Malaria - Drugs In Development, 2023’, provides an overview of the Malaria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRTX-1133 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRTX-1133 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRTX-1133 in Pancreatic Ductal Adenocarcinoma Drug Details: MRTX1133 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Malaria [Strain 7G8] Vaccine in Malaria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Malaria [Strain 7G8] Vaccine in Malaria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Malaria [Strain 7G8] Vaccine in Malaria Drug Details:Vaccine candidate is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – malaria [strain NF-54] vaccine 2 in Malaria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - malaria [strain NF-54] vaccine 2 in Malaria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Malaria [Strain Nf-54] Vaccine 2 in Malaria Drug Details:Vaccine candidate...
-
Track & Monitor
Innovation in pharma: anti-malarial peptides
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s anti-malarial peptides segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Track & Monitor
Environmental Sustainability in Pharmaceuticals: Anti-malarial compositions
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Anti-malarial compositions segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...